Scarica l'app Stockscreener
8.51
0.00%
0.00
Dopo l'orario di chiusura:
8.51
Y Mabs Therapeutics Inc Borsa (YMAB) Ultime notizie
Y-mAbs soars on take-private deal with SERB Pharmaceutical - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA, YMAB, DNOW on Behalf of Shareholders - The Malaysian Reserve
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WideOpenWest, Inc. (NYSEWOW), BankFinancial Corporation (NasdaqBFIN), STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nas - Morningstar
Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Brookline Capital Management - MarketBeat
Can Y mAbs Therapeutics Inc. scale operations efficientlyPredictable High Return Ideas - classian.co.kr
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Lowered by Truist Financial - MarketBeat
DeFi Technologies Provides Monthly Corporate Update: Valour Reports US$947 Million (C$1.3 Billion) in AUM, and Monthly Net Inflows of US$14.4 Million (C$19.8 Million) in July 2025, Among Other Key Developments - The Globe and Mail
Y-mAbs Therapeutics (NASDAQ:YMAB) Given Hold Rating at Jones Trading - MarketBeat
11 Best Short-Term Stocks to Invest in - Insider Monkey
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Neutral" Rating from HC Wainwright - MarketBeat
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) - Eastern Progress
SERB Pharmaceuticals Acquires Y-MAbs As Revenue Slides - Finimize
Y-mAbs Therapeutics 2025 Q2 Earnings Narrowed Losses and Pending Acquisition - AInvest
Y-mAbs Therapeutics Reports Q2 Earnings and Acquisition - TipRanks
Y-mAbs (YMAB) Q2 Revenue Falls 14% - AOL.com
Y-mAbs Therapeutics Q2 Earnings: Revenue Meets Expectations, EPS Below Consensus - AInvest
Y-mAbs Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Y mAbs Therapeutics earnings beat by $0.19, revenue topped estimates - Investing.com Canada
Y-mabs sold to Serb Pharmaceuticals for USD 412m - medwatch.com
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates - sharewise.com
Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders - The Joplin Globe
Y-mAbs (YMAB) Q2 Revenue Falls 14% - The Motley Fool
Y-mAbs Therapeutics, Inc. SEC 10-Q Report - TradingView
Y-mAbs Therapeutics, Inc. Q2 2025 Financial Results - TradingView
Y-mAbs Q2 rev. $19.5mln, exceeds guidance, acquires Y-mAbs for $412mln. - AInvest
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments - The Manila Times
Y-mAbs Acquisition: SERB Pays 105% Premium in $412M Deal While Q2 Revenue Exceeds Guidance - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, YMAB, HLVX on Behalf of Shareholders - The Malaysian Reserve
A Look Ahead: Y-mAbs Therapeutics's Earnings Forecast - 富途牛牛
Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc.YMAB - Business Wire
Y-mAbs Q2 2025 Earnings Tomorrow: Key Updates Coming Amid SERB Pharma Transaction - Stock Titan
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains? - MSN
Mayer Brown advises the group Serb Pharmaceuticals on the structuring of the take-private of Y-mAb Therapeutics Inc. - Mayer Brown
BSR REIT ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS - The Globe and Mail
YmAbs Therapeutics' 103.3% Surge: A Sustainable Bull Case or a Volatile Flash in the Pan? - AInvest
Y-mAbs Therapeutics Stock Surges 103.3% on Acquisition Deal with SERB Pharmaceuticals - AInvest
Y-mAbs Therapeutics: A Biotech M&A Deal that Highlights the Value and Challenges of the Industry - AInvest
Y-mAbs Therapeutics: The Next Deal Showcases The Value And Challenges Of Biotech M&A - Seeking Alpha
Oppenheimer Downgrades Y-mAbs Therapeutics to Market Perform From Outperform, Adjusts Price Target to $3 From $4 - MarketScreener
Canaccord Genuity Downgrades Y-mAbs Therapeutics to Hold From Buy, Adjusts Price Target to $8.60 From $26 - MarketScreener
SERB Pharma to acquire Y-mAbs Therapeutics for $412m - World Pharmaceutical Frontiers
Wedbush Downgrades Y-mAbs Therapeutics to Neutral From Outperform, Cuts Price Target to $8.60 From $18 - MarketScreener
Truist Downgrades Y-mAbs Therapeutics to Hold From Buy, Cuts Price Target to $8.60 From $14 Amid SERB Deal - MarketScreener
Y-mAbs Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
SERB bets on rare cancer drug in $412 million deal for Y-mAbs - The Pharma Letter
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know - MSN
Y-mAbs stock soars over 100% after acquisition deal with SERB S.A.S. - Mugglehead Magazine
Y-mAbs Therapeutics downgraded to Hold from Buy at Canaccord - TipRanks
Y-mAbs Therapeutics stock downgraded to Hold by Truist after SERB acquisition - Investing.com Canada
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):